| Institution: | 1. NRG Oncology/NSABP Foundation, Pittsburgh;2. Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh;3. Dana-Farber Cancer Institute, Harvard Medical School, Boston;4. Harvard T.H. Chan School of Public Health, Boston;5. Frontier Science Foundation, Boston;6. Department of Biostatistics, University of Pittsburgh, Pittsburgh, USA;7. Oncology Biometrics Department, AstraZeneca, Macclesfield;8. Department of Data Management, Frontier Science (Scotland), Kincraig, Scotland, UK;9. Department of Oncology R&D, AstraZeneca, Gaithersburg, USA;10. Research Operations Department, Breast International Group, Brussels, Belgium;11. Global Oncology Clinical Development, Merck and Co. Inc., Rahway, USA;12. Department of Medical Oncology, The Christie Hospital NHS Foundation Trust Manchester, UK;13. European Organisation for Research and Treatment (EORTC), Brussels, Belgium;14. The Department of Medical Oncology, Institut Bergonie, Bordeaux, France;15. Medical Oncology Department, Vall d’Hebron Institute of Oncology and Vall d’Hebron University Hospital, Barcelona, Spain;16. Department of Oncology-Pathology, Swedish Breast Cancer Group, Karolinska Institute and Breast Cancer Center, Karolinska University Hospital and Karolinska Comprehensive Cancer Center, Stockholm, Sweden;17. Department of Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK;18. Department of Cancer Medicine, Institute Gustave Roussy and Unicancer Breast Group, Paris, France;19. Department of Medicine, Basser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA;20. Odette Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada;21. Department of Clinical Research, Instituto de Oncologia De Rosario, Santa Fe, Argentina;22. Department of Medicine/Oncology, Stanford University School of Medicine, Stanford;23. Facing Our Risk of Cancer Empowered, Tampa, USA;24. Department of Medical Oncology, BC Cancer, Vancouver, Canada;25. Department of Oncology, International Breast Cancer Study Group, Bern, Switzerland;26. Department of Medical Oncology, Ospedale Infermi AUSL della Romagna, Rimini, Italy;27. Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;28. Department of Late Development Oncology, AstraZeneca, Cambridge, UK;29. Department of Internal Medicine, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea;30. Department of Medical Oncology, Dutch Breast Cancer Research Group, Utrecht, the Netherlands;31. Department of Medical Oncology, Landspítali University Hospital of Iceland, Icelandic Breast Cancer Group, Reykjavik, Iceland;32. Department of Anatomical Pathology, The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia;33. Department for Obstetrics and Gynecology, Universitaetsklinikum, University of Ulm, Ulm, Germany;34. Department of Oncology, Sahlgrenska University Hospital, Gothenburg;35. Department of Oncology, The Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden;36. Division of Cancer Research, National Health Research Institutes, Taiwan Cooperative Oncology Group, Taipei City, Taiwan;37. Department of Hematology, Oncology, and Radiation Physics, Swedish Association of Breast Oncologists, Skåne University Hospital, Lund, Sweden;38. Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, The National Cancer Institute, Rockville, USA;39. Medicine and Research, German Breast Group, Neu-Isenburg;40. Medicine and Research, The Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt, Germany;41. Department of Pathology, UPMC Hillman Cancer Center, Pittsburgh, USA;42. Medical Faculty Mannheim, Heidelberg University, Mannheim Germany and the German Breast Group, Neu-Isenburg, Germany;43. Médica Consorcio Hospitalario Provincial de Castellón, Servicio de Oncología, Castellón, Spain;44. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne;45. Breast Cancer Trials, Australia and New Zealand, Newcastle, Australia;46. Department of Scientific Direction, Institut Jules Bordet, l’Université Libre de Bruxelles, Brussels;47. Department of Research and Development, Breast International Group, Brussels, Belgium;48. The Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany;49. Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland;50. Fudan University Shanghai Cancer Center, Shanghai, China;51. Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, USA;52. Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;53. Department of Patient Advocacy, Europa Donna-The European Breast Cancer Coalition, Milan, Italy;54. Europa Donna Slovenia, Ljubljana, Slovenia;55. Department of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany;56. Department of Breast Surgery Kyoto University Hospital, Kyoto, Japan;57. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA;58. Department of Pathology, University of Milan, European Institute of Oncology IRCCS, Milan;59. Internal Medicine Oncology Unit, Gruppo Oncologico Italiano di Ricerca Clinica, Parma;60. Università degli Studi di Genova and IRCCS Ospedale Policlinico San Martino, Genoa, Italy;61. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;62. Department of Oncology, Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva;63. Faculty of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;64. Department of Breast Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou;65. Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China;66. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;67. Department of Medical Oncology, Breast Cancer Unit, Oscar Lambret Center, Lillie, France;68. Department of Breast Surgery, First Hospital of Jilin University, Jilin, China;69. Department of Medical Oncology, Centre Henri Becquerel, Rouen, France;70. Breast Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China;71. Chemotherapy Department B, Országos Onkológiai Intézet, National Institute of Oncology, Budapest, Hungary;72. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands;73. Department of Breast Surgery, Peking Union Medical College Hospital, Peking, China;74. Breast Unit, Royal Marsden Hospital, London, UK;75. Division of Medical Senology, European Institute of Oncology (IEO), IRCCS, Milan;76. Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany;77. Department of Internal Medicine, Section of Hematology/Oncology, Oklahoma University Health, Oklahoma City, USA;78. The Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel;79. Edinburgh Cancer Research Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh;80. Department of Statistics and Programming, Frontier Science (Scotland), Kincraig, Scotland;81. The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London;82. The Breast Cancer Now Unit, Guy’s Hospital Cancer Centre, King’s College London, London, UK |
